PP
ESPR icon

PDT Partners’s Esperion Therapeutics ESPR Stock Holding History

PDT Partners’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-28,779
Closed -$179K – 615
2022
Q4 		$179K Sell
28,779
-18,359
-39% -$131K 0.03% 550
2022
Q3 		$316K Sell
47,138
-90,735
-66% -$623K 0.05% 568
2022
Q2 		$877K Sell
137,873
-36,442
-21% -$207K 0.08% 436
2022
Q1 		$809K Sell
174,315
-66,520
-28% -$285K 0.07% 439
2021
Q4 		$1.2M Buy
240,835
+120,007
+99% +$961K 0.09% 323
2021
Q3 		$1.46M Buy
120,828
+16,428
+16% +$239K 0.1% 293
2021
Q2 		$2.21M Buy
104,400
+87,622
+522% +$2.11M 0.15% 259
2021
Q1 		$471K Buy
+16,778
New +$495K 0.03% 524
2020
Q3 		– Sell
-92,200
Closed -$4.73M – 761
2020
Q2 		$4.73M Sell
92,200
-11,367
-11% -$476K 0.32% 123
2020
Q1 		$3.27M Buy
103,567
+34,167
+49% +$1.8M 0.26% 119
2019
Q4 		$4.14M Buy
69,400
+5,094
+8% +$229K 0.26% 120
2019
Q3 		$2.36M Sell
64,306
-33
-0.1% -$1.31K 0.14% 183
2019
Q2 		$2.99M Buy
+64,339
New +$3.02M 0.18% 148
2017
Q2 		– Sell
-315,100
Closed -$11.1M – 532
2017
Q1 		$11.1M Buy
315,100
+270,200
+602% +$6.19M 0.58% 29
2016
Q4 		$562K Sell
44,900
-900
-2% -$10.7K 0.04% 385
2016
Q3 		$634K Buy
+45,800
New +$519K 0.04% 351

Other funds holding ESPR

Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

PDT Partners's ESPR Position: Q1 2023 in Review

PDT Partners sold out of Esperion Therapeutics (ESPR) in Q1 2023, closing a stake of 28,779 shares — an estimated $179K sold.

PDT Partners first reported a position in ESPR in Q3 2016 and held it in 16 quarters. The position peaked at $11.1M in Q1 2017. 164 funds tracked by Wall St. Rank hold ESPR as of Q1 2023.

  • PDT Partners reported no remaining Esperion Therapeutics position as of Q1 2023 after selling out during the quarter.
  • PDT Partners sold 28,779 Esperion Therapeutics shares in Q1 2023, an estimated $179K.
  • PDT Partners first reported a position in Esperion Therapeutics in Q3 2016 and held it in 16 quarters.
  • PDT Partners's Esperion Therapeutics position peaked at $11.1M in Q1 2017.
  • 164 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2023.

Based on PDT Partners's 13F filing for Q1 2023, filed 15 May 2023.